4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28
      European journal of cancer (Oxford, England : 1990)
      Elsevier BV
      Biomarker, Bladder cancer, C-reactive protein, CRP flare, CRP flare-Response, Immune checkpoint blockade, Immunotherapy, Long-flare, Metastatic urothelial carcinoma

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Robust biomarkers to predict response to immune checkpoint blockade (ICB) in metastatic urothelial carcinoma (mUC) are still in demand. Recently, early C-reactive protein (CRP) kinetics and especially the novel CRP flare-response phenomenon has been associated with immunotherapy response.

          Related collections

          Author and article information

          Journal
          Eur J Cancer
          European journal of cancer (Oxford, England : 1990)
          Elsevier BV
          1879-0852
          0959-8049
          May 2022
          : 167
          Affiliations
          [1 ] Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: niklas.kluemper@ukbonn.de.
          [2 ] Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Erlangen. Electronic address: Danijel.sikic@uk-erlangen.de.
          [3 ] Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Germany. Electronic address: Jonas.saal@ukbonn.de.
          [4 ] Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: Thomas.Buettner@ukbonn.de.
          [5 ] Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: Franziska.Goldschmidt@ukbonn.de.
          [6 ] Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: Jonas.Jarczyk@medma.uni-heidelberg.de.
          [7 ] Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Electronic address: Becker.philippega@gmail.com.
          [8 ] Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Electronic address: Philip.Zeuschner@uks.eu.
          [9 ] Department of Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany. Electronic address: weinke_m@ukw.de.
          [10 ] Department of Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany. Electronic address: Kalogirou_C@ukw.de.
          [11 ] Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany. Electronic address: Jbreyer@caritasstjosef.de.
          [12 ] Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany. Electronic address: mburger@caritasstjosef.de.
          [13 ] Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: philipp.nuhn@medma.uni-heidelberg.de.
          [14 ] Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: karlh.tully@gmail.com.
          [15 ] Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany. Electronic address: Florian.Roghmann@elisabethgruppe.de.
          [16 ] Department of Urology, University Hospital Ulm, Ulm, Germany. Electronic address: christian.bolenz@uniklinik-ulm.de.
          [17 ] Department of Urology, University Hospital Ulm, Ulm, Germany. Electronic address: Friedemann.Zengerling@uniklinik-ulm.de.
          [18 ] STRATIFYER Molecular Pathology GmbH, Cologne, Germany. Electronic address: ralph.wirtz@stratifyer.de.
          [19 ] Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Institute of Pathology, University Medical Center Bonn (UKB), Bonn, Germany. Electronic address: muderslab@gmail.com.
          [20 ] Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany; Institute of Pathology, University Medical Center Bonn (UKB), Bonn, Germany. Electronic address: glen.kristiansen@ukbonn.de.
          [21 ] Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: tobias.bald@ukbonn.de.
          [22 ] Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: joerg.ellinger@ukbonn.de.
          [23 ] Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Erlangen. Electronic address: bernd.wullich@uk-erlangen.de.
          [24 ] Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: Michael.hoezel@ukbonn.de.
          [25 ] Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Erlangen; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. Electronic address: Arndt.hartmann@uk-erlangen.de.
          [26 ] Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: philipp.erben@medma.uni-heidelberg.de.
          [27 ] Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany. Electronic address: manuel.ritter@ukbonn.de.
          [28 ] Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Erlangen; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany. Electronic address: markus.eckstein@uk-erlangen.de.
          Article
          S0959-8049(22)00120-4
          10.1016/j.ejca.2022.02.022
          35366569
          c7b805f9-46e3-407b-b65e-975d5ea98318
          History

          Metastatic urothelial carcinoma,Biomarker,Bladder cancer,C-reactive protein,CRP flare,CRP flare-Response,Immune checkpoint blockade,Immunotherapy,Long-flare

          Comments

          Comment on this article

          scite_
          27
          1
          27
          0
          Smart Citations
          27
          1
          27
          0
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content118

          Cited by13